Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVWLET)

• Drug Name: ABBV-154 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DMVWLET

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[4]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[5]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[6]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[7]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[8]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[9]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[10]
Etanercept	DMCV109	Arthritis	FA20	Approved	[11]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[12]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT05068284) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04888585) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs). U.S.National Institutes of Health.
• [3] Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC). J Med Chem. 2023 Sep 14;66(17):12544-12558.
• [4] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [5] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [6] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [7] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [8] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [9] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [10] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [11] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [12] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [13] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.